ArticleFrontiers in neurology2026
Estimated plasma volume status and the risk of 30-day mortality among patients with traumatic brain injury: analysis from the MIMIC-IV database.
Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Plasma volume status (PVS) is an indicator of fluid status, and fluid balance is linked to the prognosis of critically ill patients. This analysis aimed to examine the association of estimated PVS (ePVS) with mortality risk among traumatic brain injury (TBI) patients. Methods: This retrospective cohort analysis extracted TBI patient data from the Medical Information Mart for Intensive Care-IV (MIMIC-IV) database spanning 2008-2022. ePVS was calculated using the Duarte formula (Duarte-ePVS) and the Kaplan-Hakim formula (KH-ePVS), respectively. The associations of Duarte-ePVS and KH-ePVS with 30-day mortality risk among TBI patients were examined Results: The analysis cohort comprised 1,440 TBI patients, survival outcomes showed 247 (17.15%) deaths and 1,193 (82.85%) survivors at 30-day follow-up. A 1-SD (standard deviation) increase in KH-ePVS levels [HR (95%CI) = 1.17 (1.02-1.34)] and KH-ePVS levels ≥11.458 [HR = 1.43 (1.06-1.95)] were linked to an elevated risk of 30-day mortality. No significant relationships of high Duarte-ePVS levels and Duarte-ePVS levels ≥7.134 with 30-day mortality risk were found ( Conclusion: Elevated KH-ePVS levels were associated with an increased risk of short-term mortality among TBI patients, indicating a potential role for KH-ePVS levels in risk assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.